Multistep, sequential control of the trafficking and function of the multiple sulfatase deficiency gene product, SUMF1 by PDI, ERGIC-53 and ERp44. by Fraldi A. et al.
Multistep, sequential control of the trafficking and
function of the multiple sulfatase deficiency gene
product, SUMF1 by PDI, ERGIC-53 and ERp44
Alessandro Fraldi1,{, Ester Zito1,{, Fabio Annunziata1, Alessia Lombardi1, Marianna Cozzolino2,
Maria Monti2, Carmine Spampanato1, Andrea Ballabio1,3, Piero Pucci2, Roberto Sitia4,{ and
Maria Pia Cosma1,{,
1Telethon Institute of Genetics and Medicine (TIGEM), Via P. Castellino 111, 80131 Naples, Italy, 2CEINGE Advanced
Biotechnology and Department of Organic Chemistry and Biochemistry, Federico II University, Via Comunale
Margherita 482, 80145 Napoli, Italy, 3Department of Pediatrics, Faculty of Medicine, Federico II University,
Via S. Pansini 5, 80131 Naples, Italy and 4DIBIT-HSR, Vita-Salute San Raffaele University, Via Olgettina 58,
20132 Milan, Italy
Received February 21, 2008; Revised April 16, 2008; Accepted May 23, 2008
Sulfatase modifying factor 1 (SUMF1) encodes for the formylglicine generating enzyme, which activates sul-
fatases by modifying a key cysteine residue within their catalytic domains. SUMF1 is mutated in patients
affected by multiple sulfatase deficiency, a rare recessive disorder in which all sulfatase activities are
impaired. Despite the absence of canonical retention/retrieval signals, SUMF1 is largely retained in the endo-
plasmic reticulum (ER), where it exerts its enzymatic activity on nascent sulfatases. Part of SUMF1 is secreted
and paracrinally taken up by distant cells. Here we show that SUMF1 interacts with protein disulfide isomer-
ase (PDI) and ERp44, two thioredoxin family members residing in the early secretory pathway, and with
ERGIC-53, a lectin that shuttles between the ER and the Golgi. Functional assays reveal that these inter-
actions are crucial for controlling SUMF1 traffic and function. PDI couples SUMF1 retention and activation
in the ER. ERGIC-53 and ERp44 act downstream, favoring SUMF1 export from and retrieval to the ER, respect-
ively. Silencing ERGIC-53 causes proteasomal degradation of SUMF1, while down-regulating ERp44 pro-
motes its secretion. When over-expressed, each of three interactors favors intracellular accumulation. Our
results reveal a multistep control of SUMF1 trafficking, with sequential interactions dynamically determining
ER localization, activity and secretion.
INTRODUCTION
Sulfatases are a large family of prokaryotic and eukaryotic
enzymes that catalyze the hydrolysis of ester sulfates, their
natural substrates. The consensus sequence of the sulfatase
catalytic domain contains a cysteine that is modified to for-
mylglycine (FGly) within the endoplasmic reticulum (ER)
by SUMF1/FGE (sulfatase modifying factor/formylglicine
generating enzyme), herein called SUMF1 for brevity (1).
This unique post-translation modification is essential for sulfa-
tase activity: mutations in the SUMF1 gene result in the inac-
tivity of all the sulfatases and cause multiple sulfatase
deficiency in humans (2,3).
SUMF1/FGE was crystallized and recognized to utilize
oxygen to generate FGly in the sulfatases via a cysteine sulfe-
nic acid intermediate (4). Of the eight cysteines present in
SUMF1, cysteines 50 and 52 can form intermolecular disulfide
bonds yielding SUMF1 homodimers (5,6). Cysteines 336 and
341 are part of the active site of SUMF1, are essential for its
function and can exist in different oxidation states (4,7).
Recently, we have demonstrated that SUMF1 is also
secreted: when taken up by other cells it is re-localized to
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the ER, where it activates endogenous sulfatases (8). SUMF1
does not contain an ER retention signal, and how its ER local-
ization, secretion and uptake are controlled is still puzzling.
Another interesting question is whether and how the activity
of SUMF1 is coupled to its trafficking.
To dissect out the mechanisms controlling its folding,
trafficking and function, we searched for proteins interacting
with SUMF1 and focused on molecules potentially involved
in its retention/escape from the ER. Using flagged SUMF1
as a bait, several proteins were co-immunoprecipitated and
identified by mass spectrometry (MS). Among others, we
further analyzed three specific interactors, PDI (protein
disulfide isomerase), ERp44 and ERGIC-53 as strong candi-
dates to control SUMF1 function and trafficking. PDI is an
ER resident, multifunctional protein that catalyzes the
oxidation, reduction and isomerization of disulfide bonds
and acts as a redox sensitive chaperone (9). It consists of
four thioredoxin-like domains, abb’a’. The a and a’ domains
contain CxxC redox-active motifs and are required for
oxidase activity. The b and b’ domains serve structural
functions, participate in substrate binding and are essential
for disulfide isomerization (10–12).
ERp44 is a soluble protein of the thioredoxin family (TRX)
endowed with an ER-localization signal, RDEL (13), that also
accumulates in the ERGIC (ER–Golgi intermediate compart-
ment) and cis-Golgi (14–16). It is responsible for thiol-
mediated retention of many substrate proteins, including
Ero1a, adiponectin and IgM (15–17). ERp44 has been impli-
cated also in ER calcium homeostasis, binding and regulating
IP3R1 (18).
ERGIC-53 is a membrane-bound lectin protein that cycles
between the ER and Golgi, accumulating in the ERGIC.
ERGIC-53 operates as a cargo receptor (19), capturing
certain glycoproteins (e.g. Factors V and VIII, pro-catZ) in
the ER and releasing them in the Golgi in a pH-dependent
manner (20). ERGIC-53 is also the cargo receptor for the
LDL receptor-related protein (LRP). It dissociates it from
the RAP protein, which blocks LRP-ligand interactions in
the early secretory pathway (21). Subsequently, RAP is
recycled back to the ER, and LRP proceeds through the
Golgi and to secretion. In association with ERp44,
ERGIC-53 can assist IgM polymerization (15).
Biochemical and functional assays reveal that PDI retains
and activates SUMF1 into the ER, whereas ERGIC-53 and
ERp44 exert their activity downstream by exporting the
enzyme from, and retrieving it back into the ER, respectively.
The interactions with PDI, ERGIC-53 and ERp44 provide a
novel, dynamic control of SUMF1 trafficking and enzymatic
activity.
RESULTS
Identification of proteins controlling SUMF1 function
and trafficking
SUMF1 modifies sulfatases as they enter into the ER (22).
However, it does not contain known ER localization
signal(s). Furthermore, a fraction of SUMF1 can be secreted
and taken up by vicinal cells, where it re-localizes to the
ER and activates sulfatases (8). In an attempt to identify
SUMF1 interactors controlling its subcellular localization
and secretion, extracts from stable HeLa cells expressing
SUMF1-3xFlag (HL3xFS1 clone) (8) were immunoprecipi-
tated with immobilized anti-Flag antibodies. Upon compe-
tition with a Flag peptide, the eluate was analyzed by
nanoLC MS/MS and compared with immunoprecipitates
from mock-transfected HeLa cells (unpublished data).
Among the bands yielding a much higher intensity in the
HL3xFS1 lysates, we identified SUMF2, previously shown
to form heterodimers with SUMF1 (23) and several novel pro-
teins including PDI, ERp44, ERGIC-53 and ERp57, another
thiol-disulfide oxidoreductase (24). We further analyzed
these novel interactors as strong candidates for the control of
SUMF1 trafficking and localization (Supplementary Material,
Table S1).
PDI binding to SUMF1 is mediated by both covalent
and non-covalent interactions
To confirm and characterize the association of SUMF1 with
PDI, HeLa cells were transfected with SUMF1-Flag, PDI, or
the mutant PDIASAS that lacks the four active cysteines in a
and a’ domains (25). In cells over-expressing only SUMF1-
Flag, two main bands of 40 and 80 kDa, likely corresponding
to monomers and covalent homodimers (23), were decorated
by anti-Flag under non-reducing conditions (Fig. 1A, lane
1). Co-expression of wild-type (wt) PDI drastically decreased
the intensity of the SUMF1 homodimers band (lane 2). Two
slower migrating bands become detectable (lane 2, see aster-
isk) likely corresponding to covalent PDI–SUMF1 heterodi-
mers and higher order complexes. These bands disappeared
in reducing conditions (unpublished data), were not detectable
in cells co-transfected with SUMF1-Flag and the redox-
inactive PDIASAS mutant (Fig. 1A, lane 3) and were stained
by anti-PDI antibodies (Fig. 1B, lane 2). These experiments
demonstrated that PDI binds covalently with SUMF1, and
strongly decreases the formation of SUMF1 homodimers. To
test if PDI and SUMF1 can also associate via non-covalent
interactions the same extracts were immunoprecipitated with
anti-Flag. The immunocomplexes were resolved under non-
reducing conditions and blots decorated with anti-PDI.
Specific bands corresponding to PDI–SUMF1 heterodimers
and PDI monomers demonstrated covalent and non-covalent
interactions between SUMF1 and PDI, respectively (Fig. 1B,
lane 2). In contrast, SUMF1 and PDIASAS formed mainly non-
covalent associations since only the band correspondent to
PDI monomers was detectable (Fig. 1B, lane 3, lower band).
Of note, a low level of non-covalent association between
endogenous PDI and SUMF1 was also seen (Fig. 2B, lane
1). To confirm these results, HL3xFS1 cells transfected with
either PDI or PDIASAS were immunoprecipitated with anti-
Flag. Equal amounts of the immunocomplexes were loaded in
reducing gels and the amount of PDI co-immunoprecipitated
with SUMF1-Flag evaluated by anti-PDI blotting. Clearly,
some endogenous PDI co-immunoprecipitated with SUMF1-
Flag (Fig. 1C, lane 1). The PDI band was more intense in
cells over-expressing PDI with respect to cells over-expressing
PDIASAS which cannot interact covalently with its substrates
(Fig. 1C, lanes 2 and 3). These results demonstrate that PDI
associates with SUMF1 covalently, via the cysteines in a
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and a’ active sites. Non-covalent interactions also take place,
as confirmed by the observation that also PDIASAS binds
SUMF1.
PDI–SUMF1 interactions were also confirmed by their
co-distribution upon cell fractionation experiments in Optiprep
density gradients (8–24%). SUMF1 monomers and dimers
were abundant in the densest ER fractions containing PDI
(Supplemantary material, Fig. S1).
N-glycan-dependent interactions between SUMF1
and ERGIC-53
Also ERGIC-53 was identified as a molecule capable of
binding SUMF1. To validate the SUMF1-ERGIC-53 inter-
action, we over-expressed SUMF1-Flag in a stable HeLa
transfectant that can be induced to express a tagged version
of wt ERGIC-53 [KKFF; (26)]. Lysates of cells cultured
without tetracycline and expressing both transgenes were
immunoprecipitated with anti-ERGIC-53 antibodies. A band
corresponding to SUMF1-Flag was clearly detected both in
the absence and presence of dithiobis(succinimidylpropionate)
(Fig. 2A, lane 2). In agreement with low affinity interactions,
more SUMF1 was co-immunoprecipitated after cross-linking
(Fig. 2A, compare lanes 2), although similar amounts of
ERGIC-53 were precipitated by anti-ERGIC-53 antibodies
(unpublished data). Mock-IP, PoIP and 20% of the lysates
were also analyzed to control the specificity and efficiency
of immunoprecipitation (lanes 1, 3, 4). To exclude that the
interactions observed were due to over-expression, we
analyzed non-transfected HeLa cells (panel B). Specific inter-
actions between the endogenous proteins were detected: bands
with the mobility and immunoreactivity of over-expressed
SUMF1 (run in lane 3 to facilitate identification of the band)
were precipitated by anti-ERGIC-53 also without cross-
linking (Fig. 2B, lanes 1 and 2), but not by control antibodies
(lane 4).
ERGIC-53 is a lectin that binds substrate glycoproteins
via its carbohydrate recognition domain (CRD) in a Ca2þ-
dependent way (19). To investigate whether also the associ-
ation between SUMF1 and ERGIC-53 was mediated via
carbohydrate–lectin interactions, we transfected HeLa cells
expressing tetracycline-inducible ERGIC-53N156A, a CRD
inactive mutant (19) with SUMF1-Flag. ERGIC-53N156A
does not bind substrates and acts as a dominant-negative
mutant, recruiting wt ERGIC-53 into hetero-hexameric com-
plexes (27). Consistent with a role of the CRD in binding
SUMF1, ERGIC-53N156A did not associate with SUMF1
and inhibited its co-immunoprecipitation with endogenous
ERGIC-53 (Fig. 2C, upper panel; compare lane 3 that shows
the association of SUMF1-Flag with endogenous ERGIC-53
and lane 1 that shows association of SUMF1-Flag with the
left-over endogenous ERGIC-53 not recruited into the hetero-
hexameric complex). Next, we transfected KKFF cells with
SUMF1N141A-Flag, a non-glycosylated SUMF1 mutant (8).
Consistent with carbohydrate–lectin-dependent interactions,
non-glycosylated SUMF1 mutant did not associate with
Figure 1. PDI binding to SUMF1. (A) Formation of stable PDI–SUMF1 mixed disulfides. HeLa cells were co-transfected with SUMF1-Flag and PDI or
PDIASAS. The cells were treated with N-ethylmaleimide to quench disulfide interchange. Aliquots of the lysates were resolved by non-reducing gradient
SDS–PAGE gels. The filters were revealed with anti-Flag antibody. Asterisks indicate bands corresponding to SUMF1-PDI mixed disulfides. (B–C) PDI associ-
ation with SUMF1 is mediated also by non-covalent interactions. Transient (B) or stable (C, HL3xFS1 cells), HeLa transfectants expressing SUMF1-Flag were
transfected with PDI or PDIASAS. Protein extracts were immunoprecipitated with anti-Flag antibody and the immunocomplexes were resolved under non-
reducing (B) or reducing (C) conditions and blots probed with anti-PDI antibodies.
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ERGIC-53 (Fig. 2C, lanes 5 and 7, lower panels). These data
demonstrate that binding of SUMF1 and ERGIC-53 is
mediated by N-glycan–lectin interactions.
Thiol-dependent interactions between SUMF1 and ERp44
The interactions between SUMF1-Flag and endogenous
ERp44 were confirmed in 293T and HeLa cells (Fig. 2D).
Non-reducing gels revealed the presence of a dithiothreitol-
sensitive band with motility (86 kDa) and immunoreactivity
consistent with a SUMF1–ERp44 disulfide complex
(Supplementary Material, Fig. S2). Interestingly, ERp44
homodimers (17) became barely detectable in cells over-
expressing SUMF1-Flag (Supplementary Material, Fig. S2),
suggesting that SUMF1–ERp44 intermolecular interactions
competed with ERp44 homodimerization and might involve
ERp44 Cys29, as for other substrates of thiol-mediated
quality control (13,16,17). Accordingly, unlike wt ERp44,
the ERp44C29S mutant did not co-precipitate SUMF1
(Fig. 2E, compare lanes 5, 8, upper panel), confirming that
Figure 2. SUMF1 binds ERGIC-53 and ERp44 via glycan- and thiol-dependent interactions. (A) Co-precipitation between SUMF1 and ERGIC-53. KKFF cells
incubated for 48 h without tetracycline to induce expression of myc-ERGIC53 were transfected with or without SUMF1-Flag and then immunoprecipitated with
anti-ERGIC-53 antibodies before or after cross-linking with dithiobis(succinimidylpropionate) (DSP). Immunoprecipitates were resolved under reducing con-
ditions and blots decorated with anti-Flag to reveal exogenous SUMF1 molecules associating with ERGIC-53. (B) Interactions between endogenous SUMF1
and ERGIC-53. Extracts from untransfected HeLa cells were immunoprecipitated as in A and blots decorated with anti-SUMF1 to detect endogenous molecules.
Over-expressed SUMF1 was run in lane 3 to facilitate identification of the relevant band. (C) Binding between SUMF1 and ERGIC-53 is N-glycan dependent.
ERGIC-53N156A or ERGIC-53KKFF cells were transfected with SUMF1-Flag or non-glycosylated SUMF1N141A-Flag as indicated, incubated for 48 h+
tetracycline to modulate ERGIC-53 expression and cross-linked with DSP. IP and Western blotting of the immunocomplexes were carried out with the indicated
antibodies. (D) Endogenous ERp44 associates with over-expressed SUMF1. HeLa and 293T cells were transfected with the SUMF1-Flag-expressing plasmid.
The extracts were immunoprecipitated with anti-Flag antibodies and blots probed with anti-ERp44. (E) Over-expression of Ero1a inhibits the association
between SUMF1 and ERp44. HeLa cells were transfected with SUMF1-Flag, HA-ERp44, HA-ERp44C29S and Myc-ERO1a, as indicated. Cell extracts
were immunoprecipitated with anti-Flag antibodies and blots probed with anti-HA or anti-Flag.
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efficient binding largely depends on Cys29 of ERp44. Similar
data were independently obtained by Mariappan et al. (6).
From the latter study, it appears that a mutant ERp44 in
which Cys 29 was replaced by Alanine, bound non-covalently
to SUMF1. The discrepant behavior of the two mutants could
reflect the different hydrophilicity of the two residues used to
replace the cysteine in the active site.
The specificity and functional relevance of the ERp44–
SUMF1 interaction was further underscored by experiments
in which ERp44 was co-expressed with Ero1a, an oxidase
that establishes strong interactions with ERp44. When over-
expressed, Ero1a inhibits the interactions between ERp44
and its endogenous partners (16,17). In a similar way, Ero1a
competed with SUMF1 for binding to ERp44 (Fig. 2E, lanes
10–15). These data demonstrate that ERp44 interacts cova-
lently with SUMF1 via Cys 29 and this interaction can be
inhibited by active Ero1a.
Subcellular distribution of SUMF1
Next, we determined the co-distribution of SUMF1 with PDI,
ERp44 and ERGIC-53 by triple and double immunofluores-
cence (IF) staining (Fig. 3A). As expected, we found that
most SUMF1 co-localizes with PDI in the ER, as also pre-
viously shown (3) as well as with ERp44. Co-localization of
SUMF1 with ERGIC-53 was detectable in ER, while it was
poorly if at all evident in the ERGIC perhaps because inter-
actions are very transient in this compartment. This suggests
that endogenous SUMF1 is efficiently and rapidly retrieved
to the ER. The distribution of SUMF1 in different compart-
ments of the early secretory apparatus was confirmed by cell
fractionation experiments in Optiprep density gradients.
SUMF1 immunoreactivity was abundant in the densest frac-
tions containing most PDI and part of ERp44. However, a
minor amount of SUMF1 co-distributed with ERp44 and
ERGIC-53 within the less dense fractions (Fig. 3B).
PDI, ERGIC-53 and ERp44 co-operatively modulate
SUMF1 retention/secretion and its enzymatic activity
Having confirmed that SUMF1 establishes specific inter-
actions with PDI, ERp44 and ERGIC-53, we tested their
role in the subcellular localization of SUMF1. First, we deter-
mined whether the over-expression of PDI, PDIASAS or
PDIDKDEL, a mutant lacking the C-terminal KDEL sequence
and hence secreted (15,28) impacted SUMF1 traffic. As shown
in Fig. 4A, PDI prevented SUMF1 secretion and increased its
intracellular accumulation (Fig. 4A, lanes 1 and 2), indicating
that PDI can retain SUMF1. PDIASAS had a smaller effect on
SUMF1 retention/secretion, reflecting its capability of estab-
lishing non-covalent interactions (Fig. 4A, lane 3). As
expected, the secretable PDIDKDEL mutant impacted margin-
ally SUMF1 localization. Interestingly, ERp57, another thiol-
disulfide oxidoreductase identified in the MS analysis as a
SUMF1 interactor, also inhibited SUMF1 secretion (Fig. 4A,
lane 5). These results were confirmed by quantitative pulse
and chase assays (Fig. 4B). Clearly, wt PDI was more efficient
than PDIASAS, PDIDKDEL and ERp57 in favoring the intra-
cellular retention of SUMF1.
Next, we analyzed their effects on the activity of IDS, a sul-
fatase that depends on SUMF1 to exert its enzymatic function.
When IDS activity was measured in the extracts of the PDI
over-expressing cells, a significant increase in IDS activity
(compared with mock not-transfected cells) was observed. In
contrast, PDIASAS, PDIDKDEL had a slight inhibitory effect
on IDS activity, whereas ERp57 did not affect IDS activity
(Fig. 4C). The stimulatory effects of PDI were specific since
ERp57, although retaining SUMF1, did not impact SUMF1-
dependent IDS activity. These results were confirmed by the
findings that PDI wt, but not its mutants or ERp57, enhanced
the activity of over-expressed IDS in the presence or absence
of over-expressed SUMF1 (Supplementary Material, Fig. S3A).
Furthermore, to confirm that PDI controls SUMF1 retention
and activity, we silenced PDI in HeLa cells. A significant
decrease of SUMF1 in the cellular pellet with an increase of
secretion was observed in the interfered cells (Fig. 4D).
Accordingly, IDS and SGSH activities were significantly
decreased upon PDI silencing (Fig. 4D). Importantly, the
inhibitory effect was not due to lower sulfatases protein
levels, as the amount of SGSH remained constant upon PDI
silencing (Fig. 4D). The inhibitory effects of down-regulating
PDI were even more evident in cells over-expressing IDS and
SUMF1 (Supplementary Material, Fig. S3B). These findings
indicate that PDI controls retention of SUMF1 and modulates
the activity of SUMF1 and of sulfatases in a redox-dependent
way.
Next, we examined the effect of modulating the ERGIC-53
or ERp44 levels on retention/secretion of SUMF1. When
ERGIC-53 was over-expressed, little if any effect was
observed compared with mock not-transfected HeLa cells
(unpublished data), suggesting that ERGIC-53 is not rate-
limiting for SUMF1 transport. However, expression of
KKAA ERGIC-53, a mutant that accumulates in the ER
(29), caused intracellular accumulation of SUMF1, at the
expense of the secreted fraction (Fig. 5A). Since the KKAA
mutant is known to act as a dominant negative for ERGIC-53-
dependent transport (26), these findings confirm that func-
tional interactions occur between ERGIC-53 and SUMF1.
The effects of ERp44 over-expression on SUMF1 retention/
secretion were next evaluated. When increasing amounts of
HA-ERp44 were co-transfected with SUMF1-Flag in HeLa
cells, secretion of SUMF1 was strongly reduced (Fig. 5B).
Interestingly, the co-expression of HA-ERp44 and two increas-
ing amounts of Ero1a resulted in increased secretion of
SUMF1-Flag (Supplementary Material, Fig. S4A), likely
owing to the preferential association between ERp44 and
Ero1a. An increase in endogenous SUMF1 secretion was
also observed upon over-expression of Ero1a (Supplementary
Material, Fig. S4B) or treatment of cells with
b-mercaptoethanol (Supplementary Material, Fig. S4C).
These results demonstrated that the association of either
ERGIC-53 or ERp44 impacts SUMF1 localization/secretion
and that formation of intermolecular disulfide bonds is critical
for SUMF1 retention.
To further dissect the function of ERGIC-53 and ERp44 in
controlling SUMF1 trafficking we depleted HeLa cells of
either or both proteins by silencing assays. Intriguingly, upon
ERGIC-53 silencing the amount of SUMF1 detectable in cell
extracts sensibly decreased with respect to controls, but the
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fraction of SUMF1 secreted into the media was not significantly
increased (Fig. 5C). Silencing ERp44 also caused a similar
decrease in the intracellular pool of SUMF1. However, differ-
ently from what observed with ERGIC-53-specific siRNAs,
reducing ERp44 levels increased SUMF1 secretion (Fig. 5D).
As expected, the loss of intracellular SUMF1 in ERGIC-53-
and ERp44-depleted HeLa cells caused a significant decrease
in the activity of different sulfatases (Fig. 5C and D). Like-
wise, cells from a ERp44þ/2 ES trapped clone had lower
ARSC, IDS and SGSH activities, further confirming that the
ERp44-mediated retention is important for guaranteeing
SUMF1 function (Fig. 5E). Taken together, these data
suggest that both ERp44 and ERGIC-53 modulate SUMF1
trafficking and activity; however, they have a different func-
tion. ERp44 plays an important role in localizing SUMF1 in
the ER, likely through RDEL-dependent retrieval from distal
stations of the early secretory apparatus, as also recently
suggested (15).
Binding to ERGIC-53 inhibits proteasomal degradation
of SUMF1
Why would ERGIC-53 silencing cause loss of intracellular
SUMF1 without simultaneous secretion? We hypothesized
that the loss of SUMF1 was caused by increased degradation.
To test this hypothesis, we cultured HeLa ERGIC-53- and
ERp44-interfered cells in the presence or absence of the pro-
teasome inhibitor N-acetyl-leucyl-leucyl-norleucinal (LLN).
Clearly, SUMF1 was stabilized by LLN in ERGIC-53 silenced
cells (Fig. 6A, compare lanes 5 and 6), but not in ERp44-
silenced or mock-treated cells. As expected, increased
secretion of SUMF1 was seen in cells silenced for ERp44.
In fact, proteasome inhibition did not affect the amounts of
secreted SUMF1.
To further confirm that the absence of ERGIC-53 caused
degradation of SUMF1, we performed pulse-chase experiments
using HL3xFS1 cells silenced for either ERp44 or ERGIC-53. In
untreated cells, SUMF1 was relatively stable. In contrast, silen-
cing of ERp44 or of ERGIC53 caused a marked decrease in the
amount of intracellular SUMF1-Flag (Fig. 6B). Consistent with
the previous results, a simultaneous increase of SUMF1
secretion was seen upon ERp44 silencing, but not in the
medium of ERGIC-53 siRNA cells (Fig. 6B). During the
chase, this result was reverted after addition of proteasome
inhibitors that stabilized SUMF1 only in ERGIC-53-interfered
cells (Fig. 6C). Taken together, these findings indicated that
ERGIC-53 depletion increased proteasomal degradation of
SUMF1 and that part of it could still be secreted possibly via
lectin-independent mechanisms; this is also supported by the
observation that non-glycosylated SUMF1 is also secreted (8).
Figure 3. Subcellular distribution of SUMF1. (A) Immunofluorescence localization of SUMF1 within PDI, ERp44 and ERGIC-53 enriched compartment. HeLa
cells were co-stained with fluorescent antibodies specific for SUMF1, ERp44, PDI, Calreticulin and ERGIC-53, as indicated. Scale bar, 5 mm. (B)
Co-fractionation of SUMF1, ERp44, ERGIC-53 and PDI. Postnuclear cellular membranes from HeLa cells were fractionated by continuous Optiprep gradients
(8–24%). Twenty different fractions were collected and resolved in SDS-gels under reducing conditions. Blots were probed for SUMF1, ERp44, ERGIC-53 or
PDI, as indicated.
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In contrast, ERp44 depletion leads to loss of intracellular
SUMF1 that is not degraded but efficiently secreted.
The results shown so far suggested that soon after transloca-
tion in the ER, SUMF1 folds and interacts with PDI. The redox
competency of PDI is important for the SUMF1-dependent acti-
vation of sulfatases in the ER. Part of SUMF1 binds to ERGIC-53
that likely delivers it to the cis-Golgi. Here ERp44 retrieves
SUMF1 to the ER in an RDEL-dependent mechanism.
In the above scenario, a fraction of SUMF1 should be
present in ERGIC and cis-Golgi: this was confirmed by cell
fractionation experiments in Optiprep density gradients.
However, triple and double IF staining of non-transfected
HeLa cells revealed that the vast majority of SUMF1 accumu-
lates in PDI-containing compartments (Fig. 3A). Only traces
of it could be detected in ERGIC-53 and/or ERp44-positive
downstream compartments. These observations suggest that
endogenous SUMF1 is efficiently and rapidly retrieved to
the ER, a notion that is consistent to the low level of
SUMF1 secretion by non-transfected cells.
However, consistent with the biochemical and functional data
shown in Figures 5 and 6, silencing ERp44 or ERGIC-53 had
profound effects on the subcellular distribution of SUMF1. In
both ERp44- and ERGIC-53-silenced cells, the fraction of
SUMF1 co-localizing with the ER markers was drastically
reduced (Supplementary Material, Fig. S5). While in
ERGIC-53-depleted cells we observed primarily a loss of intra-
cellular staining, consistent with the observed proteasomal
degradation of SUMF1 (see Supplementary Material, Fig. S5).
DISCUSSION
SUMF1 activates all sulfatases in the ER operating a post-
translational oxidation of a specific cysteine of their catalytic
domain (22). However, SUMF1 lacks ER localization
signals and part of it is secreted in the medium. How are
these features harmonized and regulated? We identified three
proteins, PDI, ERGIC-53 and ERp44 that by orchestrating
Figure 4. PDI controls ER retention and activity of SUMF1. (A and B) SUMF1 retention/secretion upon over-expression of PDI wt, PDI mutants and ERp57. (A)
HeLa cells were transfected with PDI, PDIASAS, PDIDKDEL or ERp57 expression plasmids. Two days after transfection, proteins extracts from cellular pellets
deriving from 2  106 cells and the correspondent media (conditioned for 16 hours) were probed with anti-SUMF1. Anti-tubulin antibodies were used as loading
controls. (B) HL3xFS1 stable cells transfected with PDI, PDIASAS, PDIDKDEL or ERp57 expression plasmids were pulsed with [
35S] aminoacids for 15 min.
Pellets and media were collected at the indicated chase times and immunoprecipitated with anti-Flag antibody to reveal SUMF1-Flag proteins. The amount of
SUMF1 recovered in the pellet and in the medium at different chase times is quantified as the percentage of total SUMF1 present in cells at time 0 (100%). (C)
PDI potentiates intracellular IDS activity. Forty-eight hours after transfection the activity of IDS was quantified in cellular extracts, and expressed as the per-
centage relative to the activity of mock transfected cells. (D) Silencing of PDI affects retention and activity of SUMF1. HeLa cells were mock transfected or
transfected with PDI-directed siRNA expressing plasmid. Twenty-four hour after transfection cell pellets and the correspondent conditioned media were analyzed
by Western-Blotting with the indicated specific antibodies (left). The IDS and SGSH activities were measured in the same extracts. Data are expressed as fold
induction relative to mock transfected cells (right).
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the balance between SUMF1 retention in the ER and its
secretion modulate its activity. After its translocation into
the ER, SUMF1 must fold. It does so likely under the assist-
ance of resident chaperones, lectins and enzymes, including
calnexin and ERp57. Indeed, peptides derived from the latter
two molecules were also found in our MS analyses (see Sup-
plementary Material, Table S1).
Once folded, a large fraction of SUMF1 must remain in the
ER, so as to exert its function on incoming sulfatases. Increas-
ing or decreasing PDI levels show that the interaction with
PDI is important in maintaining SUMF1 in the ER. PDI is a
redox-dependent chaperone that mediates the formation, iso-
merization and reduction of disulfide bridges of numerous sub-
strates, through the formation of transient mixed disulfides. In
general, it is difficult to trap these intermediates in living cells,
unless the second cysteine in the PDI CxxC motifs, which
resolves the intermediates, is deleted. SUMF1 is clearly a
special substrate of PDI, in that abundant heterodimers are
easily detected in cells, provided that disulfide interchange
reactions are inhibited by alkylants. In this respect, SUMF1
has profound similarities with Ero1a (25). Our data also
demonstrate that the redox activity of PDI is essential for
SUMF1 function. The ASAS mutant, that lacks all four
cysteines in the a and a’ domains, fails to potentiate sulfatase
activities. In addition, ERp57 over-expressing cells display
normal sulfatase activity despite their larger pool of intracellu-
lar SUMF1. These experiments suggest that retention can be
uncoupled from activation and that PDI might act as a cofactor
in the SUMF1-dependent sulfatase activation. PDI increases
sulfatase activity, also without the concomitant SUMF1 over-
expression. This observation may reflect increased folding of
IDS, further activation on endogenous SUMF1, or both. It is
also possible that PDI favors the interaction between
SUMF1 and IDS, acting as a binding platform or maintaining
the key cysteines involved in sulfatase modifications in a
reaction-competent state. Whatever the exact mechanism(s)
Figure 5. ERGIC-53 and ERp44 control SUMF1 traffic and activity. (A) ERGIC-53KKAA retains SUMF1 in the ER. Conditioned media (16 h) and lysates of
KKAA cells cultured for 48 h+ tetracycline were analyzed by Western blotting with the indicated antibodies. (B) Over-expression of ERp44 inhibits SUMF1
secretion. HeLa cells were transfected with SUMF1-Flag alone or with increasing levels of HA-ERp44. Western blotting of conditioned media (16 h) and cellular
extracts was carried out with the indicated antibodies. (C) Silencing ERGIC-53 causes loss of intracellular SUMF1 without increasing its secretion. HeLa cells
were transfected with fluorescent ERGIC-53-directed siRNA or control duplexes. 3 days after transfection the cellular pellets and media (16 h conditioned) were
probed with the indicated antibodies. Different sulfatases activities were measured in protein extracts obtained from FACS-sorted cells to enrich siRNA-treated
cells. (D) Silencing ERp44 increases SUMF1 secretion. HeLa cells were transfected with fluorescent ERp44 siRNA and control duplexes. 3 days after transfec-
tion cell pellets and media (16 h conditioned) were probed with the indicated antibodies. The indicated sulfatases activities were measured in protein extracts
obtained from FACS-sorted cells to enrich siRNA-treated cells. (E) Increased SUMF1 secretion in ERp44þ/2 ES cells. Different sulfatases activities were
measured in extracts of ES trapped clones containing a single copy of ERp44 gene. The activities were compared to control ES wt cells.
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involved, our data imply that PDI folds, retains and activates
SUMF1 in the ER.
However, the life cycle of SUMF1 is not limited to the ER:
part of it is secreted and taken up in distant cells (Fig. 7). How
does SUMF1 embark into secretion? Our results identify
SUMF1 as a novel ERGIC-53 substrate. ERGIC-53 mediates
the forward transport of selected glycoproteins (19). It inter-
acts with SUMF1 via its CRD domain, and could hence
promote its export from the ER via COPII-coated vesicles.
Once in the cis-Golgi, the lower pH might favor SUMF1disso-
ciation from ERGIC-53 (Fig. 7), as described for other sub-
strates (20). Surprisingly, the destiny of SUMF1 in the
absence of ERGIC-53 entails proteasomal degradation,
rather than ER accumulation. This observation suggests that
degradation and export are in competition for a fraction of
SUMF1 molecules (30). Whether and how the molecules
that are rapidly degraded in ERGIC-53-depleted cells differ
from the stable SUMF1 pool is at presently unknown.
Once in the cis-Golgi, SUMF1 can proceed with forward
membrane traffic or bind to ERp44 and be retrieved into the
ER (Fig. 7). This notion is supported by several lines of evi-
dence: first, over-expression of active ERp44 inhibits
secretion. Second, SUMF1-ERp44 mixed disulfides are
easily detected in different cell types. Third, impairment of
ERp44 function increases significantly the secretion of the
enzyme. Similar findings have been recently obtained inde-
pendently (6). An intriguing difference emerged with our
studies is that a Cys29Ala ERp44 mutant retained SUMF1
binding capabilities (6). The different phenotypes observed
with the two ERp44 mutants might be explained with the
insertion of a more hydrophilic residue in position 29, and
hence within the active binding site, that could partially
inhibit the non-covalent interactions that ERp44 establishes
with its client proteins.
In all cell lines analyzed so far, ERp44 localizes also down-
stream of the ER, and a considerable fraction accumulates in
the ERGIC and cis-Golgi. In these compartments, ERp44 is
thought to capture oxidative folding intermediates (e.g. IgM,
adiponectin) and retrieve them to the ER via RDEL-dependent
mechanisms (15,16). Our data suggest that ERp44 rapidly
retrieves SUMF1 back into the ER (Fig. 7). Therefore,
ERp44 is essential for SUMF1 function, as cells depleted of
ERp44 secrete SUMF1 and nascent sulfatases will be partially
inactivated thereof.
Confocal IF and subcellular fractionation analyses reveal
that in untransfected HeLa cells most SUMF1 is present in
compartments that are positive for PDI. Therefore, little
SUMF1 is present in compartments downstream of the ER
at steady state. Nonetheless, silencing either ERGIC-53 or
ERp44 causes a significant decrease in the total intracellular
SUMF1 pool, and a redistribution of the remaining molecules
that can be documented by microscopy and fractionation
assays. Taken together, these findings suggest a highly
dynamic localization mechanism.
Figure 6. Different fate of SUMF1 in cells lacking ERGIC-53 or ERp44. (A) Proteasomal degradation of SUMF1 in ERGIC-53-depleted cells. HeLa cells were
transfected with ERp44- or ERGIC53-specific siRNA or control duplexes, as indicated, and cultured with or without the proteasome inhibitor LLN for 12 h.
Cellular pellets and media were probed with the indicated specific antibodies. Note the increased secretion in ERp44-depleted cells, and the increased intracellu-
lar pool in LLN-treated cells only in cells silenced for ERGIC-53. (B) Increased SUMF1 secretion upon ERp44, but not ERGIC-53 silencing. HL3xFS1 stable
cells were transfected with ERp44- or ERGIC53-specific siRNA or control duplexes and then pulsed, chased and handled as in Figure 4B. (C) ERGIC-53 silen-
cing promotes proteasomal degradation of SUMF1. The lysates of cells treated as above were collected after a 7 h chase carried out in presence or absence of the
proteasome inhibitor LLN.
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Many chaperones and enzymes reside in the ER because
they possess C-terminal KDEL-like sequences. Their
absence in SUMF1 suggests that an evolutionary pressure
exists that favors the multi-level localization control described
here, allowing regulated secretion. Particularly relevant in this
context is the observation that over-expression of active Ero1a
increases SUMF1 secretion, which may reflect competition
with ERp44 and/or enforced dimerization of SUMF1
through cysteines 50–52 (5). In analogy with adiponectin,
SUMF1 could be rapidly secreted in response to Ero1a-
dependent redox changes.
In conclusion, SUMF1 can be retained into the ER or secreted
into the extracellular matrix, depending on the concerted action
of PDI, ERp44 and ERGIC-53, and this multistep control modu-
lates in turn its activity on sulfatases. Our data reveal a fine tuned
localization mechanism involving recycling of enzymatically
active, transport-competent molecules. This dual localization
provides a pool of SUMF1 molecules easily mobilized into
secretion. The identified multistep control of interactions
tunes the amounts of circulating SUMF1. Increased secretion
of SUMF1 upon certain physiological stimuli, e.g. ER hyperox-
idation, might thus allow an additional level of regulation of the
sulfatase activities in some cells and tissues.
MATERIALS AND METHODS
Cells and reagents
KKFF, KKAA and N156A cells were gifts from H.-P. Hauri
(University of Basel). ERp44þ/2 ES cells (clone # XR1070)
were purchased from Mutant Mouse Regional Resource
Center (MMRRC). Antibodies: monoclonal and polyclonal
anti-calreticulin from ABCAM, monoclonal anti-ERGIC53
from Alexis, monoclonal anti-SUMF1 from R&D, rabbit
anti-Myc from Santa Cruz Biotechnology, polyclonal
anti-PDI (kind gift from Ineke Braakman, Utrecht, NL), mono-
clonal anti-Flag, monoclonal anti-b-tubulin and polyclonal
anti-HA from Sigma. The ERp44-specific monoclonal 2D5,
36C9 are available in our laboratory and previously described
(15). The ERp44-HA, ERp44C29S-HA, Myc-Ero1a, IDS,
SUMF1-Flag, SUMF1N141A-Flag, PDI, PDIASAS, PDIDK-
DEL and ERp57 expressing plasmids were previously
described (8,13,17,23,25). The proteasome inhibitor LLN
was purchased from Sigma.
Immunoaffinity purification of SUMF1-associated proteins
SUMF1 complexes were affinity purified from total extracts
prepared from 6  108 HL3XFS1 cells (stable HeLa cells
expressing SUMF1-3XFlag). Cells were washed in PBS and
lysed in 50 mM Tris/HCl, pH 7.9, 200 mM NaCl, 0.5%
Triton, 1 mM EDTA, 50 mM HEPES and protease inhibitors
(Sigma). After clarification, extracts were incubated with M2
anti-FLAG agarose-conjugated antibody (Sigma) overnight,
followed by extensive washes with BC100 buffer (100 mM
NaCl, 10% glycerol, 20 mM Tris/HCl, pH 7.9, 0.1% NP40)
and FLAG peptide elution in BC100. The eluted extracts
were TCA precipitated before loading onto 5–20% SDS–
PAGE. The gels were stained with colloidal Coomassie blue
(Invitrogen). Protein bands were excised and analyzed by MS.
Figure 7. SUMF1 trafficking: a working model. Within the ER, SUMF1 folds and interacts with PDI. The redox activity of PDI is important for the SUMF1-
dependent activation of sulfatases. SUMF1 also binds to ERGIC-53 through lectin–glycan interactions. This interaction protects SUMF1 form proteasomal
degradation and delivers it to the cis-Golgi. Here, part of SUMF1 is retrieved by ERp44 through RDEL-dependent mechanisms and part of it can move
forward and reach the medium. Secreted SUMF1 can be taken up as previously shown (8).
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siRNA transfection
Cells were transiently transfected with siRNA duplexes using
a 5 nM final oligonucleotide concentration with the Lipofecta-
mine RNAiMax reagent (Invitrogen), according to manufac-
turer instructions. The siRNA duplexes were purchased from
Qiagen; the sequences of the siRNA oligonucleotides against
ERGIC-53 were as previously described (31): 50-GGACAG
AAUCGUAUUCAUCdTdT-30 and 50-GAUGAAUACGAUU
CUGUCCdTdT-30. The sequences of ERp44 siRNA oligonu-
cleotides were as previously described (15): 50-CAACUCUG
GCAAACACUAC-30 and 30-UUGAGACCGUUUGUGAUG
-30. PDI silencing was obtained by transfection with a
pSilencer2.1-U6 neo vector expressing a siRNA for human
PDI [(a kind gift of Dr K. Ahn (Seoul, Korea) (32)].
Cross-linking and immunoprecipitation
This technique is performed following the protocol of Appen-
zeller et al. (19).
MS, sulfatase enzymatic activity assays, non-reducing
and reducing western-blotting
These techniques were carried out as previously described (8).
Immunofluorescence staining
Cells were grown on coverslips and fixed in PBS (pH 7.4) 4%
paraformaldehyde for 20 min. The cells were permeabilized
for 15 min in 0.1% Tween in PBS and then incubated for
30 min in PBS, 10% FBS (blocking). Cells were then incu-
bated with appropriate primary and secondary antibodies
(diluted in PBS þ 1% FBS). Coverslips were mounted in Vec-
tashield (Vector Laboratories) and viewed under confocal
microscopy (Leica TCS SP2 AOBS confocal microscope
with a x63 Neofluor Pan-Apo 1.3-nm oil objective).
Preparation of cellular membranes, Optiprep density
sedimentation and immunoblotting
Cellular membranes from human HeLa cells as well as the
Optiprep gradients were prepared according to the manufac-
turer’s instruction. All fractions were dissolved in reducing
and not-reducing sample buffer, resolved on 10% SDS–
PAGE, transferred to PVDF and immunoblotted.
Pulse-chase assays
HL3xFS1 cells were transfected with control or ERGIC-53- or
ERp44-specific siRNA oligos. Seventy-two hours after trans-
fection, the cells were starved for 30 min in methionine/
cysteine-free DMEM and then labeled for 15 min in the
same medium containing [35S]-met and [35S]-cys (Amersham
Promix). Cells and media were then collected at different time
points after the pulse. Cell pellets were lysed in 50 mM Tris/
HCl, pH 7.9, 200 mM NaCl, 0.5% Triton, 1 mM EDTA,
50 mM HEPES and protease inhibitors (Sigma). Cell extracts
and media were subjected to immunoprecipitation with
anti-Flag antibodies and the immunocomplexes resolved on
SDS–gels. Radio-labeled proteins were revealed and densito-
metrically quantified by phosphoimaging analysis (Typhoon,
Amersham).
Data analysis
Data were analyzed by one-way analysis of variance. A
P-value ,0.05 was considered to be statistically significant.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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